Avitinib (BioDeep_00000801612)
代谢物信息卡片
化学式: C26H26FN7O2 (487.2131908)
中文名称: 艾维替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC4=C(C=CN4)C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)F
InChI: InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, DrugBank
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
2 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D11308
- PubChem: 72734520
- DrugBank: DB15327
- ChEMBL: CHEMBL4297865
- CAS: 1557267-42-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Qiling Tang, Hongce Chen, Zihao Mai, Han Sun, LingJun Xu, Guihao Wu, Zhuang Tu, Xuecheng Cheng, Xiaoping Wang, Tongsheng Chen. Bim- and Bax-mediated mitochondrial pathway dominates abivertinib-induced apoptosis and ferroptosis.
Free radical biology & medicine.
2022 02; 180(?):198-209. doi:
10.1016/j.freeradbiomed.2022.01.013. [PMID: 35063650] - Lu Wang, Lian Guo, Yixiang Wang, Renhua Guo, Zhaoqiang Xu, Zhengzhen Gao, Lijun Xie, Juan Chen, Ying Chen, Yun Liu, Hongwen Zhang, Lihua Bao, Wanhong Xu, Mingshe Zhu, Feng Shao, Yongqian Shu. Metabolic disposition of [14 C]-abivertinib, an epidermal growth factor receptor tyrosine kinase inhibitor: Role of glutathione conjugation.
British journal of clinical pharmacology.
2021 03; 87(3):1475-1485. doi:
10.1111/bcp.14555. [PMID: 32959915] - Yong Shi, Deru Meng, Shuanghu Wang, Peiwu Geng, Tao Xu, Quan Zhou, Yunfang Zhou, Wanshu Li, Xugao Chen. Effects of Avitinib on CYP450 Enzyme Activity in vitro and in vivo in Rats.
Drug design, development and therapy.
2021; 15(?):3661-3673. doi:
10.2147/dddt.s323186. [PMID: 34456561] - Qingjun Wu, Hui Jiang, Shuanghu Wang, Dapeng Dai, Feifei Chen, Deru Meng, Peiwu Geng, Hongfeng Tong, Yunfang Zhou, Debiao Pan, Quan Zhou, Chunjie Wang. Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats.
Thoracic cancer.
2020 10; 11(10):2775-2781. doi:
10.1111/1759-7714.13587. [PMID: 32812378] - Xin Zheng, Weicong Wang, Yanbao Zhang, Yuxiang Ma, Hongyun Zhao, Huitao Gao, Pei Hu, Ji Jiang. Development of an LC-MS/MS method for quantifying two main metabolites of abivertinib in human plasma.
Biomedical chromatography : BMC.
2020 Feb; 34(2):e4704. doi:
10.1002/bmc.4704. [PMID: 31629371] - Shujuan Huang, Jiajia Pan, Jing Jin, Chengying Li, Xia Li, Jiansong Huang, Xin Huang, Xiao Yan, Fengling Li, Mengxia Yu, Chao Hu, Jingrui Jin, Yu Xu, Qing Ling, Wenle Ye, Yungui Wang, Jie Jin. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
Cancer letters.
2019 Oct; 461(?):132-143. doi:
10.1016/j.canlet.2019.07.008. [PMID: 31310800] - Yi-Chen Zhang, Zhi-Hong Chen, Xu-Chao Zhang, Chong-Rui Xu, Hong-Hong Yan, Zhi Xie, Shao-Kun Chuai, Jun-Yi Ye, Han Han-Zhang, Zhou Zhang, Xiao-Yan Bai, Jian Su, Bin Gan, Jin-Ji Yang, Wen-Feng Li, Wei Tang, Feng Roger Luo, Xiao Xu, Yi-Long Wu, Qing Zhou. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
EBioMedicine.
2019 May; 43(?):180-187. doi:
10.1016/j.ebiom.2019.04.030. [PMID: 31027916] - Yuxiang Ma, Xin Zheng, Hongyun Zhao, Wenfeng Fang, Yang Zhang, Jieying Ge, Lu Wang, Weicong Wang, Ji Jiang, Shaokun Chuai, Zhou Zhang, Wanhong Xu, Xiao Xu, Pei Hu, Li Zhang. First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2018 07; 13(7):968-977. doi:
10.1016/j.jtho.2018.03.025. [PMID: 29626621]